Bhishamjit S Chera1, David Fried2, Alex Price2, Robert J Amdur3, William Mendenhall3, Chiray Lu4, Shiva Das2, Nathan Sheets2, Lawrence Marks5, Panayiotis Mavroidis2. 1. Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Lineberger Comprehensive Cancer Center, University of North Carolina Hospitals, Chapel Hill, North Carolina. Electronic address: bchera@med.unc.edu. 2. Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina. 3. Department of Radiation Oncology, University of Florida Hospitals, Gainesville, Florida; Shands Cancer Center, University of Florida Hospitals, Gainesville, Florida. 4. Department of Radiation Oncology, University of Florida Hospitals, Gainesville, Florida. 5. Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Lineberger Comprehensive Cancer Center, University of North Carolina Hospitals, Chapel Hill, North Carolina.
Abstract
PURPOSE/OBJECTIVE(S): To estimate the association between different dose-volume metrics of the salivary glands and pharyngeal constrictors with patient reported severity of xerostomia/dysphagia in the setting of deintensified chemoradiation therapy (CRT). METHODS AND MATERIALS: Forty-five patients were treated on a phase 2 study assessing the efficacy of deintensified CRT for favorable-risk, HPV-associated oropharyngeal squamous cell carcinoma. Patients received 60 Gy intensity modulated radiation therapy with concurrent weekly cisplatin (30 mg/m2), and reported the severity of their xerostomia/dysphagia (before and after treatment) using the patient-reported outcome version of the Common Terminology Criteria for Adverse Events (CTCAE) (PRO-CTCAE). Individual patient dosimetric data of the contralateral parotid and submandibular glands and pharyngeal constrictors were correlated with changes in PRO-CTCAE severity. A change in severity (from baseline) of ≥2 was considered clinically meaningful. Associations between dose-volume metrics and patient outcomes were assessed with receiver operating characteristic (ROC) curve and logistic regression model. RESULTS: Six months after CRT, patients reporting <2 change in xerostomia severity (n=14) had an average Dmean = 22 ± 9 Gy to the sum of the contralateral glands (parotid + submandibular) compared with the patients reporting ≥2 change (n=21), who had an average Dmean = 34 ± 8 Gy. V15 to V55 for the combined contralateral glands showed the strongest association with xerostomia (area under the curve [AUC] = 0.83-0.86). Based on the regression analysis, a 20% risk of toxicity was associated with V15 = 48%, V25 = 30%, and Dmean=21 Gy. Six months after CRT, patients reporting <2 change in dysphagia severity (n=26) had an average V55 = 76 ± 13 (%) to the superior pharyngeal constrictor compared with the patients reporting ≥2 change in severity (n=9), who had average V55 = 89 ± 13 (%). V55to V60 had the strongest association with dysphagia (AUC = 0.70-0.75). Based on the regression analysis, a 20% risk of toxicity was associated with V55 = 78%, V60 = 40%. The findings at 12 months were similar. CONCLUSIONS: After deintensified CRT, the rate of patient-reported xerostomia/dysphagia appears to be associated with the V15 of the combined contralateral salivary glands and V55 to V60 of the superior pharyngeal constrictors.
PURPOSE/OBJECTIVE(S): To estimate the association between different dose-volume metrics of the salivary glands and pharyngeal constrictors with patient reported severity of xerostomia/dysphagia in the setting of deintensified chemoradiation therapy (CRT). METHODS AND MATERIALS: Forty-five patients were treated on a phase 2 study assessing the efficacy of deintensified CRT for favorable-risk, HPV-associated oropharyngeal squamous cell carcinoma. Patients received 60 Gy intensity modulated radiation therapy with concurrent weekly cisplatin (30 mg/m2), and reported the severity of their xerostomia/dysphagia (before and after treatment) using the patient-reported outcome version of the Common Terminology Criteria for Adverse Events (CTCAE) (PRO-CTCAE). Individual patient dosimetric data of the contralateral parotid and submandibular glands and pharyngeal constrictors were correlated with changes in PRO-CTCAE severity. A change in severity (from baseline) of ≥2 was considered clinically meaningful. Associations between dose-volume metrics and patient outcomes were assessed with receiver operating characteristic (ROC) curve and logistic regression model. RESULTS: Six months after CRT, patients reporting <2 change in xerostomia severity (n=14) had an average Dmean = 22 ± 9 Gy to the sum of the contralateral glands (parotid + submandibular) compared with the patients reporting ≥2 change (n=21), who had an average Dmean = 34 ± 8 Gy. V15 to V55 for the combined contralateral glands showed the strongest association with xerostomia (area under the curve [AUC] = 0.83-0.86). Based on the regression analysis, a 20% risk of toxicity was associated with V15 = 48%, V25 = 30%, and Dmean=21 Gy. Six months after CRT, patients reporting <2 change in dysphagia severity (n=26) had an average V55 = 76 ± 13 (%) to the superior pharyngeal constrictor compared with the patients reporting ≥2 change in severity (n=9), who had average V55 = 89 ± 13 (%). V55to V60 had the strongest association with dysphagia (AUC = 0.70-0.75). Based on the regression analysis, a 20% risk of toxicity was associated with V55 = 78%, V60 = 40%. The findings at 12 months were similar. CONCLUSIONS: After deintensified CRT, the rate of patient-reported xerostomia/dysphagia appears to be associated with the V15 of the combined contralateral salivary glands and V55 to V60 of the superior pharyngeal constrictors.
Authors: Charles S Mayo; Michelle Mierzwa; Jean M Moran; Martha M Matuszak; Joel Wilkie; Grace Sun; John Yao; Grant Weyburn; Carlos J Anderson; Dawn Owen; Arvind Rao Journal: Adv Radiat Oncol Date: 2020-01-12
Authors: Stephanie G Craig; Lesley A Anderson; Michael Moran; Laura Graham; Keith Currie; Keith Rooney; Max Robinson; Victoria Bingham; Kate S Cuschieri; Stephen McQuaid; Andrew G Schache; Terry M Jones; Dennis McCance; Manuel Salto-Tellez; Simon S McDade; Jacqueline A James Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-10-30 Impact factor: 4.090
Authors: Pin-Yu Perera; Liyanage P Perera; Lyvouch Filkoski; Wen Chen; Jack H Lichy; Edina Paal; Jessica H Maxwell Journal: World J Oncol Date: 2020-02-02
Authors: Puja Aggarwal; Katherine A Hutcheson; Adam S Garden; Frank E Mott; Charles Lu; Ryan P Goepfert; Clifton D Fuller; Stephen Y Lai; G Brandon Gunn; Mark S Chambers; Erich M Sturgis; Ehab Y Hanna; Sanjay Shete Journal: Cancer Date: 2021-08-06 Impact factor: 6.860